Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature

High-risk human papillomaviruses (HPVs) are involved in the etiopathogenesis of cervical intraepithelial neoplasia (CIN) and cervical cancer. After taking HPV into account, smoking habit appears to be the most significant environmental risk factor, and the risk of this malignancy increases significantly with intensity and duration of smoking. Women with human immunodeficiency virus (HIV) infection experience a higher incidence of CIN and invasive cervical cancer. Among HIV+ women, the highly active antiretroviral therapy increases the regression rate of CIN, but the majority of these lesions do not regress to normal. As far as oral contraceptives (OCs), a systematic review of 28 studies found that, compared with never pill users, the relative risk (RR) of cervical cancer increased with increasing duration of OC use. The results were similar for squamous cell carcinoma and adenocarcinoma, and the RRs decreased after pill discontinuation. However, by weighing risks and benefits, the World Health Organization does not recommend any change in OC practice. There is no correlation between hormone replacement therapy and cervical cancer. Experimental data have shown that estradiol and progesterone can modulate the host immune response to HPV16. Prophylactic vaccination in conjunction with cervical screening is the best prevention strategy for cervical cancer.

[1]  S. de Sanjosé,et al.  The Epidemiology of Human Papillomavirus Infection and Cervical Cancer , 2007, Disease markers.

[2]  A. Ferenczy,et al.  Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. , 1997, British Journal of Cancer.

[3]  Ming Yan,et al.  Modulation of IL-6 Production during the Menstrual Cycle in Vivo and in Vitro , 2000, Brain, Behavior, and Immunity.

[4]  M. Schiffman,et al.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. , 1992, Journal of the National Cancer Institute.

[5]  S. Klein,et al.  The effects of hormones on sex differences in infection: from genes to behavior , 2000, Neuroscience & Biobehavioral Reviews.

[6]  B. Stillman,et al.  Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. , 1997, Genes & development.

[7]  M. Vessey,et al.  Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004 , 2006, British Journal of Cancer.

[8]  M. Kazatchkine,et al.  Increased Risk of Cervical Disease Among Human Immunodeficiency Virus–Infected Women With Severe Immunosuppression and High Human Papillomavirus Load , 2000, Obstetrics and gynecology.

[9]  A. P. Frank Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[10]  D Hoffmann,et al.  Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. , 1999, Cancer letters.

[11]  J. Irache,et al.  Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams. , 2006, Vaccine.

[12]  H. Stephens HIV-1 diversity versus HLA class I polymorphism. , 2005, Trends in immunology.

[13]  I. Takač,et al.  Use of various contraceptives and human papillomavirus 16 and 18 infections in women with cervical intraepithelial neoplasia , 2010, International journal of STD & AIDS.

[14]  C. Herrington,et al.  Differential cell cycle regulation by low- and high-risk human papillomaviruses in low-grade squamous intraepithelial lesions of the cervix. , 1998, Cancer research.

[15]  R. Hoover,et al.  Risk of cancer in women receiving hormone replacement therapy , 1989, International journal of cancer.

[16]  M. Stämpfli,et al.  How cigarette smoke skews immune responses to promote infection, lung disease and cancer , 2009, Nature Reviews Immunology.

[17]  N. Dyson,et al.  Molecular mechanisms of E2F-dependent activation and pRB-mediated repression , 2004, Journal of Cell Science.

[18]  K. Tamaki,et al.  Estrogen enhances immunoglobulin production by human PBMCs. , 1999, The Journal of allergy and clinical immunology.

[19]  S. Jick,et al.  Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations , 2009, Climacteric : the journal of the International Menopause Society.

[20]  M. Plummer,et al.  Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study , 2003, Cancer Causes & Control.

[21]  Young Tae Kim,et al.  Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. , 2002, Yonsei medical journal.

[22]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[23]  M. Schiffman,et al.  Human Papillomavirus Epidemiology and Public Health , 2022 .

[24]  T. Sasagawa,et al.  Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection , 2008, Journal of medical virology.

[25]  J. Schlesselman,et al.  Safety concerns and health benefits associated with oral contraception. , 2004, American journal of obstetrics and gynecology.

[26]  U. Musharrafieh,et al.  Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  M P Vessey,et al.  Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20–44 years: the UK National Case–Control Study of Cervical Cancer , 2003, British Journal of Cancer.

[28]  J. Moodley Combined oral contraceptives and cervical cancer , 2004, Current opinion in obstetrics & gynecology.

[29]  K. Matsuo,et al.  HLA-A Alleles and the Risk of Cervical Squamous Cell Carcinoma in Japanese Women , 2010, Journal of epidemiology.

[30]  G. Marshall,et al.  Perimenstrual alterations in type-1/type-2 cytokine balance of normal women. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  A. van Assche,et al.  Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. , 1995, Gynecologic and obstetric investigation.

[32]  M. Chiasson,et al.  Incidence of cervical squamous intraepithelial lesions in HIV-infected women. , 2000, JAMA.

[33]  R. Weinberg,et al.  Control of the cell cycle and apoptosis. , 1999, European journal of cancer.

[34]  Y. Rosenstein,et al.  Oestradiol potentiates the suppressive function of human CD4+ CD25+ regulatory T cells by promoting their proliferation , 2006, Immunology.

[35]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[36]  M. B. Diouf,et al.  Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. , 2003, Journal of Infectious Diseases.

[37]  S. Ziegler,et al.  Functional Analysis of FOXP3 , 2008, Annals of the New York Academy of Sciences.

[38]  A. Seidel,et al.  Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. , 1998, Carcinogenesis.

[39]  D. Chan,et al.  Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. , 2005, The Journal of infectious diseases.

[40]  S. Shapiro,et al.  Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) , 2003, Cancer Causes & Control.

[41]  Xavier Castellsagué,et al.  Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.

[42]  N. Muñoz,et al.  Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. , 2003, Journal of the National Cancer Institute. Monographs.

[43]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[44]  B. Clarke,et al.  Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. , 2001, Gynecologic oncology.

[45]  C. la Vecchia,et al.  Hormonal contraception and risk of cancer. , 2010, Human reproduction update.

[46]  A. Hoitsma,et al.  Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[47]  C. Fiorentini,et al.  The Rho-activating CNF1 toxin from pathogenic E. coli: A risk factor for human cancer development? , 2008, Infectious Agents and Cancer.

[48]  E. Androphy,et al.  Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. , 2000, Cancer research.

[49]  L. Ahdieh,et al.  Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. , 2001, The Journal of infectious diseases.

[50]  E. Kliewer,et al.  Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. , 2009, Gastroenterology.

[51]  S. Syrjänen,et al.  Papillomavirus Infections in Human Pathology , 2000 .

[52]  A. Gadducci,et al.  Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[53]  M. Oehler,et al.  Hormone replacement after gynaecological cancer. , 2010, Maturitas.

[54]  A. Schulze,et al.  Anchorage-Independent Transcription of the Cyclin A Gene Induced by the E7 Oncoprotein of Human Papillomavirus Type 16 , 1998, Journal of Virology.

[55]  E. de Villiers Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma , 2003, International journal of cancer.

[56]  C. Lees,et al.  Lack of association between cervical dysplasia and IBD: A large case–control study , 2009, Inflammatory bowel diseases.

[57]  M. Vessey,et al.  Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. , 2010, Contraception.

[58]  R. Eastell,et al.  The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. , 2001, Bone.

[59]  Wei-Yuan Zhang,et al.  A Population-based Study on the Risks of Cervical Lesion and Human Papillomavirus Infection among Women in Beijing, People's Republic of China , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[60]  V. Beral,et al.  Cervical cancer and use of hormonal contraceptives: a systematic review , 2003, The Lancet.

[61]  S. Waggoner,et al.  Identification of Tobacco- Specific Carcinogen in the Cervical Mucus of Smokers and Nonsmokers , 1997 .

[62]  E. Ploch Hormonal replacement therapy in patients after cervical cancer treatment. , 1987, Gynecologic oncology.

[63]  M. Polan,et al.  Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes. , 1992, Fertility and sterility.

[64]  J. Dillner,et al.  Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection , 2000, British Journal of Cancer.

[65]  A. Moune,et al.  Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy , 2009, Infectious Agents and Cancer.

[66]  L. Hengst,et al.  Inhibitors of the Cip/Kip family. , 1998, Current topics in microbiology and immunology.

[67]  V. Moreno,et al.  Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study , 2002, The Lancet.

[68]  Y. Hirai,et al.  Tobacco smoking and regression of low‐grade cervical abnormalities , 2010, Cancer science.

[69]  V. Beral,et al.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.

[70]  M. Diamond,et al.  Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes. , 1989, The Journal of clinical endocrinology and metabolism.

[71]  S. Gange,et al.  Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. , 2004, Journal of the National Cancer Institute.

[72]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[73]  D. Hellberg,et al.  The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. , 2005, Anticancer research.

[74]  R. Chetty,et al.  The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review , 2002, International Journal of Gynecologic Cancer.

[75]  P. Adams Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. , 2001, Biochimica et biophysica acta.

[76]  A. Berrington de González,et al.  Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis , 2004, British Journal of Cancer.

[77]  E. Korobowicz,et al.  Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. , 2009, European journal of gynaecological oncology.

[78]  S. Kjaer,et al.  Case—control study of risk factors for cervical squamous cell neoplasia in Denmark, IV: role of smoking habits , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[79]  S. Alam,et al.  The Cigarette Smoke Carcinogen Benzo[a]pyrene Enhances Human Papillomavirus Synthesis , 2007, Journal of Virology.

[80]  W. Quint,et al.  Effect of the Menstrual Cycle and Hormonal Contraceptives on Human Papillomavirus Detection in Young, Unscreened Women , 2010, Obstetrics and gynecology.

[81]  H. Yoshida,et al.  [Machinery of programmed cell death]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[82]  E. Androphy,et al.  Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. , 2000, Cancer research.

[83]  E. Villiers Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. , 2003 .

[84]  K. Beagley,et al.  Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. , 2003, FEMS immunology and medical microbiology.

[85]  S. Syrjänen,et al.  Cell Cycle Regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, Cyclin A in Predicting Cervical Intraepithelial Neoplasia, High-Risk Human Papillomavirus Infections and Their Outcome in Women Screened in Three New Independent States of the Former Soviet Union , 2006, Cancer Epidemiology Biomarkers & Prevention.

[86]  L. Zhao,et al.  Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. , 2008, Cancer research.

[87]  E. Armstrong,et al.  Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types , 2010, Journal of managed care pharmacy : JMCP.

[88]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[89]  J. Peto,et al.  Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case–control study nested within the Manchester cohort , 2000, British Journal of Cancer.

[90]  P. Sismondi,et al.  Hormone replacement therapy in cancer survivors. , 2004, Maturitas.

[91]  D. Celentano,et al.  The association of hormonal contraceptive use and HPV prevalence , 2011, International journal of cancer.

[92]  A. Lazzarin,et al.  Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. , 2001, The Journal of infectious diseases.

[93]  J. Jönsson,et al.  Systemic Reduction of Functionally Suppressive CD4dimCD25highFoxp3+ Tregs in Human Second Trimester Pregnancy Is Induced by Progesterone and 17β-Estradiol1 , 2009, The Journal of Immunology.

[94]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[95]  W. Haenszel,et al.  Cigarette smoking and invasive cervical cancer. , 1986, JAMA.

[96]  K. Anastos,et al.  Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. , 2003, Journal of the National Cancer Institute.

[97]  S. Mitrani‐Rosenbaum,et al.  Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. , 1989, The Journal of general virology.

[98]  E. Klumb,et al.  Is Higher Prevalence of Cervical Intraepithelial Neoplasia in Women With Lupus Due to Immunosuppression? , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[99]  S. Bernatsky,et al.  Malignancy in systemic lupus erythematosus: what have we learned? , 2009, Best practice & research. Clinical rheumatology.

[100]  C Dosne Pasqualini,et al.  The HLA system. , 1979, Medicina.

[101]  J. M. van der Hulst,et al.  Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.

[102]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[103]  S. Rosso,et al.  Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. , 2008, The Lancet. Oncology.

[104]  C. Schairer,et al.  Cancer incidence and mortality in women receiving estrogen and estrogen‐progestin replacement therapy—long‐term follow‐up of a Swedish cohort , 1996, International journal of cancer.

[105]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[106]  David R. Scott,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[107]  Jong Eun Lee,et al.  GSTP1 polymorphism, cigarette smoking and cervical cancer risk in Korean women. , 2002, Yonsei medical journal.

[108]  H. Burger Climacteric: The Journal of the International Menopause Society , 1998 .

[109]  M. Einstein,et al.  Issues in cervical cancer incidence and treatment in HIV , 2010, Current opinion in oncology.

[110]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[111]  A. Fiander,et al.  Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. , 2007, Vaccine.

[112]  E. Negri,et al.  Case-control study of oestrogen replacement therapy and risk of cervical cancer , 1997, BMJ.

[113]  M. Schiffman,et al.  Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.

[114]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[115]  S. Klein,et al.  Progesterone and 17β-Estradiol Enhance Regulatory Responses to Human Papillomavirus Type 16 Virus-Like Particles in Peripheral Blood Mononuclear Cells from Healthy Women , 2010, Clinical and Vaccine Immunology.

[116]  S. Jick,et al.  Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009 Sep 1:1-11. , 2010 .

[117]  J. Dillner,et al.  Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.

[118]  G. Creatsas,et al.  Oral Contraceptives and Reproductive System Cancer , 2003, Annals of the New York Academy of Sciences.

[119]  L. Hinds,et al.  Menopause, hormone replacement and gynaecological cancers , 2010, Menopause international.

[120]  J. Klein,et al.  The HLA system. First of two parts. , 2000, The New England journal of medicine.

[121]  M. von Knebel Doeberitz New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. , 2002, European journal of cancer.

[122]  N. Kiviat,et al.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. , 2003, American journal of epidemiology.

[123]  B. Patterson,et al.  Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. , 2011, Gynecologic oncology.